IOVA
Iovance Biotherapeutics (IOVA)
$
69About Iovance Biotherapeutics (IOVA)
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.
Details
Daily high
$5.93
Daily low
$5.63
Price at open
$5.86
52 Week High
$18.33
52 Week Low
$5.52
Market cap
1.7B
Dividend yield
0.00%
Volume
6.1M
Avg. volume
8.5M
P/E ratio
-3.80
Iovance Biotherapeutics News
Details
Daily high
$5.93
Daily low
$5.63
Price at open
$5.86
52 Week High
$18.33
52 Week Low
$5.52
Market cap
1.7B
Dividend yield
0.00%
Volume
6.1M
Avg. volume
8.5M
P/E ratio
-3.80